411 related articles for article (PubMed ID: 27832958)
1. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition in cardiometabolic diseases.
Koivunen P; Serpi R; Dimova EY
Pharmacol Res; 2016 Dec; 114():265-273. PubMed ID: 27832958
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of HIF-prolyl 4-hydroxylases as a promising approach to the therapy of cardiometabolic diseases.
Aitbaev KA; Murkamilov IТ; Fomin VV
Ter Arkh; 2018 Aug; 90(8):86-94. PubMed ID: 30701951
[TBL] [Abstract][Full Text] [Related]
3. HIF Activation Against CVD in CKD: Novel Treatment Opportunities.
Tanaka T; Eckardt KU
Semin Nephrol; 2018 May; 38(3):267-276. PubMed ID: 29753402
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications.
Kim SY; Yang EG
Molecules; 2015 Nov; 20(11):20551-68. PubMed ID: 26610437
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-Inducible Factor Prolyl 4-Hydroxylases and Metabolism.
Koivunen P; Kietzmann T
Trends Mol Med; 2018 Dec; 24(12):1021-1035. PubMed ID: 30391126
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of mouse transmembrane prolyl 4-hydroxylase increases blood brain barrier permeability and ischemia-induced cerebral neuroinflammation.
Byts N; Sharma S; Malm T; Kaakinen M; Korhonen P; Jaakkonen L; Keuters M; Huuskonen M; Pietilä I; Koistinaho J; Koivunen P; Myllyharju J
J Biol Chem; 2022 Mar; 298(3):101721. PubMed ID: 35151685
[TBL] [Abstract][Full Text] [Related]
7. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.
Kiriakidis S; Hoer SS; Burrows N; Biddlecome G; Khan MN; Thinnes CC; Schofield CJ; Rogers N; Botto M; Paleolog E; Maxwell PH
Kidney Int; 2017 Oct; 92(4):900-908. PubMed ID: 28506759
[TBL] [Abstract][Full Text] [Related]
8. Prolyl hydroxylase 2: a promising target to inhibit hypoxia-induced cellular metabolism in cancer cells.
Singh L; Aldosary S; Saeedan AS; Ansari MN; Kaithwas G
Drug Discov Today; 2018 Nov; 23(11):1873-1882. PubMed ID: 29772209
[TBL] [Abstract][Full Text] [Related]
9. Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection.
Requena-Ibáñez JA; Santos-Gallego CG; Rodriguez-Cordero A; Zafar MU; Badimon JJ
Cardiovasc Drugs Ther; 2022 Dec; 36(6):1187-1196. PubMed ID: 34533692
[TBL] [Abstract][Full Text] [Related]
10. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.
Sugahara M; Tanaka T; Nangaku M
Kidney Int; 2017 Aug; 92(2):306-312. PubMed ID: 28651951
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.
Kaplan JM; Sharma N; Dikdan S
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382128
[TBL] [Abstract][Full Text] [Related]
12. [Current insights into the role of HIF-PHD axis in renal anemia].
Cao JY; Liu BC
Sheng Li Xue Bao; 2018 Dec; 70(6):623-629. PubMed ID: 30560271
[TBL] [Abstract][Full Text] [Related]
13. [Hypoxia-inducible factor-prolyl hydroxylase inhibitors: the "alternative" for EPO?].
Rawee P; Eisenga MF
Ned Tijdschr Geneeskd; 2023 Sep; 167():. PubMed ID: 37823872
[TBL] [Abstract][Full Text] [Related]
14. Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors.
Wu Y; Jiang Z; You Q; Zhang X
Bioorg Med Chem; 2017 Aug; 25(15):3891-3899. PubMed ID: 28625716
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-inducible factor prolyl 4-hydroxylases: common and specific roles.
Myllyharju J; Koivunen P
Biol Chem; 2013 Apr; 394(4):435-48. PubMed ID: 23324380
[TBL] [Abstract][Full Text] [Related]
16. HIF-prolyl hydroxylases and cardiovascular diseases.
Sen Banerjee S; Thirunavukkarasu M; Tipu Rishi M; Sanchez JA; Maulik N; Maulik G
Toxicol Mech Methods; 2012 Jun; 22(5):347-58. PubMed ID: 22424133
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological targeting of the HIF hydroxylases--A new field in medicine development.
Chan MC; Holt-Martyn JP; Schofield CJ; Ratcliffe PJ
Mol Aspects Med; 2016; 47-48():54-75. PubMed ID: 26791432
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia inducible factor prolyl 4-hydroxylase enzymes: center stage in the battle against hypoxia, metabolic compromise and oxidative stress.
Siddiq A; Aminova LR; Ratan RR
Neurochem Res; 2007; 32(4-5):931-46. PubMed ID: 17342411
[TBL] [Abstract][Full Text] [Related]
19. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
Maruno S; Tanaka T; Nangaku M
Rinsho Ketsueki; 2021; 62(5):371-377. PubMed ID: 34108317
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis.
Rahtu-Korpela L; Määttä J; Dimova EY; Hörkkö S; Gylling H; Walkinshaw G; Hakkola J; Kivirikko KI; Myllyharju J; Serpi R; Koivunen P
Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):608-17. PubMed ID: 26848160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
